New Chinese patent approval for Episurf Medical
Episurf Medical (NASDAQ: EPIS B) has received another Notice of Allowance from the Chinese patent office SIPO. The patent, entitled “System and method for creating a decision support material indicating damage to an anatomical joint” covers Episurf Medical’s 3D-based damage marking technology which constitutes a central part of the Episealer® implant system. "This is a core patent for Episurf’s imaging technology, and we are happy for each additional allowance within this patent family”, comments Katarina Flodström, COO, Episurf Medical.